NEW YORK – Building on an earlier licensing partnership, BGI Genomics and Natera have launched a clinical research program to use Signatera in China for colorectal cancer patients.
The BGI China multicenter program, which launched last week, is the first clinical research application of Natera's Signatera tumor-informed residual disease test in China for use with colorectal cancer patients.
Recent data published in Clinical Cancer Research showed that Signatera can be used to stratify colorectal cancer patients based on growth or stability of their circulating tumor DNA levels over time, and the firm has previously validated the approach for early detection and prediction of impending cancer recurrence.